Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
IMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSD) can present with very similar clinical features to multiple sclerosis (MS), but the international diagnostic imaging criteria for MS are not necessarily helpful in distinguishing these two diseases. OBJECTIVE: This multicentre study tested...
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
BMJ Publishing Group
2016
|
| _version_ | 1826298780683599872 |
|---|---|
| author | Juryńczyk, M Tackley, G Kong, Y Geraldes, R Matthews, L Woodhall, M Waters, P Kuker, W Craner, M Weir, A DeLuca, G Kremer, S Leite, M Vincent, A Jacob, A de Sèze, J Palace, J |
| author_facet | Juryńczyk, M Tackley, G Kong, Y Geraldes, R Matthews, L Woodhall, M Waters, P Kuker, W Craner, M Weir, A DeLuca, G Kremer, S Leite, M Vincent, A Jacob, A de Sèze, J Palace, J |
| author_sort | Juryńczyk, M |
| collection | OXFORD |
| description | IMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSD) can present with very similar clinical features to multiple sclerosis (MS), but the international diagnostic imaging criteria for MS are not necessarily helpful in distinguishing these two diseases. OBJECTIVE: This multicentre study tested previously reported criteria of '(1) at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or (2) the presence of a subcortical U-fibre lesion or (3) a Dawson's finger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-ab NMOSD patients and also assessed their value in myelin oligodendrocyte glycoprotein (MOG)-ab positive and ab-negative NMOSD. DESIGN: Brain MRI scans were anonymised and scored on the criteria by 2 of 3 independent raters. In case of disagreement, the final opinion was made by the third rater. PARTICIPANTS: 112 patients with NMOSD (31 AQP4-ab-positive, 21 MOG-ab-positive, 16 ab-negative) or MS (44) were selected from 3 centres (Oxford, Strasbourg and Liverpool) for the presence of brain lesions. RESULTS: MRI brain lesion distribution criteria were able to distinguish RRMS with a sensitivity of 90.9% and with a specificity of 87.1% against AQP4-ab NMOSD, 95.2% against MOG-ab NMOSD and 87.5% in the heterogenous ab-negative NMOSD cohort. Over the whole NMOSD group, the specificity was 89.7%. CONCLUSIONS: This study suggests that the brain MRI criteria for differentiating RRMS from NMOSD are sensitive and specific for all phenotypes. |
| first_indexed | 2024-03-07T04:52:02Z |
| format | Journal article |
| id | oxford-uuid:d54dde40-85e3-4c78-8a0b-a274cd8388ca |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:52:02Z |
| publishDate | 2016 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:d54dde40-85e3-4c78-8a0b-a274cd8388ca2022-03-27T08:24:58ZBrain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d54dde40-85e3-4c78-8a0b-a274cd8388caEnglishSymplectic Elements at OxfordBMJ Publishing Group2016Juryńczyk, MTackley, GKong, YGeraldes, RMatthews, LWoodhall, MWaters, PKuker, WCraner, MWeir, ADeLuca, GKremer, SLeite, MVincent, AJacob, Ade Sèze, JPalace, JIMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSD) can present with very similar clinical features to multiple sclerosis (MS), but the international diagnostic imaging criteria for MS are not necessarily helpful in distinguishing these two diseases. OBJECTIVE: This multicentre study tested previously reported criteria of '(1) at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or (2) the presence of a subcortical U-fibre lesion or (3) a Dawson's finger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-ab NMOSD patients and also assessed their value in myelin oligodendrocyte glycoprotein (MOG)-ab positive and ab-negative NMOSD. DESIGN: Brain MRI scans were anonymised and scored on the criteria by 2 of 3 independent raters. In case of disagreement, the final opinion was made by the third rater. PARTICIPANTS: 112 patients with NMOSD (31 AQP4-ab-positive, 21 MOG-ab-positive, 16 ab-negative) or MS (44) were selected from 3 centres (Oxford, Strasbourg and Liverpool) for the presence of brain lesions. RESULTS: MRI brain lesion distribution criteria were able to distinguish RRMS with a sensitivity of 90.9% and with a specificity of 87.1% against AQP4-ab NMOSD, 95.2% against MOG-ab NMOSD and 87.5% in the heterogenous ab-negative NMOSD cohort. Over the whole NMOSD group, the specificity was 89.7%. CONCLUSIONS: This study suggests that the brain MRI criteria for differentiating RRMS from NMOSD are sensitive and specific for all phenotypes. |
| spellingShingle | Juryńczyk, M Tackley, G Kong, Y Geraldes, R Matthews, L Woodhall, M Waters, P Kuker, W Craner, M Weir, A DeLuca, G Kremer, S Leite, M Vincent, A Jacob, A de Sèze, J Palace, J Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title | Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title_full | Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title_fullStr | Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title_full_unstemmed | Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title_short | Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease |
| title_sort | brain lesion distribution criteria distinguish ms from aqp4 antibody nmosd and mog antibody disease |
| work_keys_str_mv | AT jurynczykm brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT tackleyg brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT kongy brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT geraldesr brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT matthewsl brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT woodhallm brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT watersp brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT kukerw brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT cranerm brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT weira brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT delucag brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT kremers brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT leitem brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT vincenta brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT jacoba brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT desezej brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease AT palacej brainlesiondistributioncriteriadistinguishmsfromaqp4antibodynmosdandmogantibodydisease |